Strides Pharma rises as its arm receives EIR from USFDA for Drug Products facility in Bengaluru
Follow us Now on Telegram ! Get daily 10 - 12 important updates on Business, Finance and Investment. Join our Telegram Channel
https://t.me/InvestmentGuruIndiacom
Download Telegram App before Joining the Channel
Strides Pharma Science is currently trading at Rs. 336.00, up by 5.10 points or 1.54 % from its previous closing of Rs. 330.90 on the BSE.
The scrip opened at Rs. 330.10 and has touched a high and low of Rs. 336.00 and Rs. 330.10 respectively. So far 2513 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 10 has touched a 52 week high of Rs. 642.10 on 15-Sep-2021 and a 52 week low of Rs. 263.45 on 11-May-2022.
Last one week high and low of the scrip stood at Rs. 339.90 and Rs. 328.55 respectively. The current market cap of the company is Rs. 2971.60 crore.
The promoters holding in the company stood at 30.37%, while Institutions and Non-Institutions held 37.84% and 31.79% respectively.
Strides Pharma Science’s biologics arm and an emerging biopharmaceutical Contract Development and Manufacturing Organization (CDMO) -- Stelis Biopharma has received the Establishment Inspection Report (EIR) from U.S. Food and Drug Administration (USFDA) for the Drug Products (DP) facility inspection that was completed at its flagship manufacturing site (Unit 2) at Bengaluru, India.
This outcome for the DP facility comes after the USFDA on-site Pre-Approval Inspection (PAI) at Stelis flagship manufacturing facility for several product submissions by the partners to the agency. The Unit 2 facility has high-end automated DP lines integrated with isolators to convert drug substances (DS) into stable formulations and fill finish within the same facility in all injectable formats, including cartridges, pen devices, auto-injectors, pre-filled syringes, liquid, and lyophilized vials.
Strides Pharma Science (Formerly Strides Shasun) is a pharmaceutical company with a major focus on development and manufacture of IP-led niche finished dosage formulations. It is also among the world’s largest manufacturers of soft gelatin capsules.
